Our first intention to treat infants’ heart failure with beta blockers was to improve the clinical condition as shown in our prospective randomized trial. We only use non-selective beta blockers in these infants, carvedilol in those with left ventricular dysfunction and propranolol in those with congenital heart disease without ventricular dysfunction. Despite a significant improvement of Ross’s heart failure score, we could not convince most colleagues within the last 25 years if the concept of neurohumoral activation in heart failure is not well-established pediatric cardiology. Recently, Honghai Liu et al. published that cardiomyocyte cytokinesis failure was increased in congenital heart disease. Inactivation of the beta adreno receptors genes and administration of the beta-blocker propranolol increased cardiomyocyte division in neonatal mice, which increased the number of cardiomyocytes (endowment) and conferred benefit after myocardial infarction in adults. We currently realize that propranolol in infants with congenital heart disease not only decrease highly elevated NT-Pro-BNP values but also decrease cardiac troponin T values that may indicate myocardial injury due to neurohumoral activation. We reproduce this observation, primarily seen in infants with congenital heart disease, in an infant with Duchenne muscular dystrophy. These observations were in good accordance with current data from H. Liu et al., who showed that treatment with non-selective beta blockers early after birth might rescue cytokinesis defects and prevent heart dysfunction in adulthood in a mouse model.
References
[1]
Liu, H., Zhang, C.H., Ammanamanchi, N., Suresh, S., Lewarchik, C., Rao, K., et al. (2019) Control of Cytokinesis by β-Adrenergic Receptors Indicates an Approach for Regulating Cardiomyocyte Endowment. Science Translational Medicine, 11, eaaw6419. https://doi.org/10.1126/scitranslmed.aaw6419
[2]
Buchhorn, R., Hulpke-Wette, M., Hilgers, R., Bartmus, D., Wessel, A. and Bursch, J. (2001) Propranolol Treatment of Congestive Heart Failure in Infants with Congenital Heart Disease: The CHF-PRO-INFANT Trial. Congestive Heart Failure in Infants Treated with Propanol. International Journal of Cardiology, 79, 167-173. https://doi.org/10.1016/S0167-5273(01)00413-2
[3]
Neves, A.L., Cabral, M., Leite-Moreira, A., Monterroso, J., Ramalho, C., Guimaraes, H., et al. (2016) Myocardial Injury Biomarkers in Newborns with Congenital Heart Disease. Pediatrics and Neonatology, 57, 488-495. https://doi.org/10.1016/j.pedneo.2015.11.004
[4]
Tarkowska, A. and Furmaga-Jablonska, W. (2012) The Evaluation of Diagnostic Role of Cardiac Troponin T (cTnT) in Newborns with Heart Defects. The Scientific World Journal, 2012, Article ID: 682538. https://doi.org/10.1100/2012/682538
[5]
Aimo, A., Januzzi Jr., J.L., Vergaro, G., Ripoli, A., Latini, R., Masson, S., et al. (2018) Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis. Circulation, 137, 286-297. https://doi.org/10.1161/CIRCULATIONAHA.117.031560
[6]
Abiko, M., Inai, K., Shimada, E., Asagai, S. and Nakanishi, T. (2018) The Prognostic Value of High Sensitivity Cardiac Troponin T in Patients with Congenital Heart Disease. Journal of Cardiology, 71, 389-393. https://doi.org/10.1016/j.jjcc.2017.09.012
[7]
El-Amrousy, D., Hassan, S. and Hodeib, H. (2018) Prognostic Value of Homocysteine and Highly Sensitive Cardiac Troponin T in Children with Acute Heart Failure. Journal of the Saudi Heart Association, 30, 198-204. https://doi.org/10.1016/j.jsha.2017.11.007
[8]
Ross, R.D., Daniels, S.R., Schwartz, D.C., Hannon, D.W., Shukla, R. and Kaplan, S. (1987) Plasma Norepinephrine Levels in Infants and Children with Congestive Heart Failure. The American Journal of Cardiology, 59, 911-914. https://doi.org/10.1016/0002-9149(87)91118-0
[9]
Toyoda, S., Haruyama, A., Inami, S., Amano, H., Arikawa, T., Sakuma, M., et al. (2017) Protective Effects of Bisoprolol against Myocardial Injury and Pulmonary dysFunction in Patients with Chronic Heart Failure. International Journal of Cardiology, 226, 71-76. https://doi.org/10.1016/j.ijcard.2016.10.046
[10]
Pascual-Figal, D.A., Manzano-Fernandez, S., Pastor, F., Garrido, I.P., Casas, T., Sanchez, Mas. J., et al. (2008) [Troponin-T Monitoring in Outpatients with Nonischemic Heart Failure]. Revista Espanola de Cardiologia, 61, 678-686. https://doi.org/10.1157/13123988
[11]
Buchhorn, R., Hulpke-Wette, M., Ruschewski, W., Ross, R.D., Fielitz, J., Pregla, R., et al. (2003) Effects of Therapeutic Beta Blockade on Myocardial Function and Cardiac Remodelling in Congenital Cardiac Disease. Cardiology in the Young, 13, 36-43. https://doi.org/10.1017/S1047951103000076
[12]
Schmid, J., Liesinger, L., Birner-Gruenberger, R., Stojakovic, T., Scharnagl, H., Dieplinger, B., et al. (2018) Elevated Cardiac Troponin T in Patients with Skeletal Myopathies. Journal of the American College of Cardiology, 71, 1540-1549. https://doi.org/10.1016/j.jacc.2018.01.070
[13]
Matsumura, T., Saito, T., Fujimura, H. and Shinno, S. (2007) Cardiac Troponin I for Accurate Evaluation of Cardiac Status in Myopathic Patients. Brain & Development, 29, 496-501. https://doi.org/10.1016/j.braindev.2007.01.009
[14]
Zhang, Y., Wang, H., Yu, X., Xing, Y., Wang, C. and He, R. (2016) Comparison Analysis of Muscle Enzymes in Children with Myocarditis and Duchene/Becker Muscular Dystrophy. Journal of Central South University Medical Sciences, 41, 984-991.
[15]
Buchhorn, R., Bartmus, D., Siekmeyer, W., Hulpke-Wette, M., Schulz, R. and Bursch, J. (1998) Beta-Blocker Therapy of Severe Congestive Heart Failure in Infants with Left to Right Shunts.The American Journal of Cardiology, 81, 1366-1368. https://doi.org/10.1016/S0002-9149(98)00175-1
[16]
Evans, D.J., MacGregor, R.J., Dean, H.G. and Levene, M.I. (2001) Neonatal Catecholamine Levels and Neurodevelopmental Outcome: A Cohort Study. Archives of Disease in Childhood Fetal and Neonatal Edition, 84, F49-F52. https://doi.org/10.1136/fn.84.1.F49
[17]
Buchhorn, R. (2019) Neurodevelopment after Critical Illness in Infancy: Stress—The Big Forgotten Player. EC Cardiology, 6, 398-406.
